Table 1.
Breast Cancer Survivor Cohorta (n = 1,361) |
Comparison Cohortb (n = 1,361) |
||||
---|---|---|---|---|---|
No. | % | No. | % | ||
Sociodemographic | |||||
Age Category at Beginning of Follow-up (years) | |||||
70–74 | 502 | 37 | 502 | 37 | |
75–79 | 417 | 31 | 417 | 31 | |
80+ | 442 | 32 | 442 | 32 | |
Race/ethnicity | |||||
Caucasian, Non-Hispanic | 1115 | 82 | 1147 | 84 | |
African-American, Non-Hispanic | 137 | 10 | 125 | 9.2 | |
Hispanic | 72 | 5.3 | 62 | 4.6 | |
Asian/Pacific Islander | 37 | 2.7 | 27 | 2.0 | |
Native American | 0 | 0 | 0 | 0 | |
Comorbidity Burden at Beginning of Follow-up | |||||
Prevalent Comorbidities included in mCCIc (index weight) | |||||
Myocardial infarction | (1) | 80 | 5.9 | 80 | 5.9 |
Congestive heart failure | (1) | 140 | 10 | 117 | 8.6 |
Peripheral vascular disease | (1) | 60 | 4.4 | 67 | 4.9 |
Cerebrovascular disease | (1) | 96 | 7.1 | 98 | 7.2 |
Dementia | (1) | 64 | 4.7 | 76 | 5.6 |
Chronic pulmonary disease | (1) | 172 | 13 | 184 | 14 |
Connective tissue disease | (1) | 36 | 2.6 | 62 | 4.6 |
Ulcer disease | (1) | 75 | 5.5 | 73 | 5.4 |
Diabetes | (1) | 202 | 15 | 169 | 12 |
Mild liver disease | (1) | 7 | 0.51 | 6 | 0.44 |
Hemiplegia | (2) | 24 | 1.8 | 25 | 1.8 |
Moderate or severe renal disease | (2) | 17 | 1.2 | 15 | 1.1 |
Diabetes with end organ damage | (2) | 31 | 2.3 | 31 | 2.3 |
Leukemia, lymphoma or tumord | (2) | 112 | 8.2 | 75 | 5.5 |
Moderate or severe liver disease | (3) | 14 | 1.0 | 2 | 0.15 |
AIDS | (6) | 0 | 0.00 | 0 | 0.00 |
Metastatic solid tumor | (6) | 6 | 0.44 | 4 | 0.29 |
Modified Charlson Comorbidity Indexe | |||||
mCCI 0 | 741 | 54 | 755 | 55 | |
mCCI 1–2 | 502 | 37 | 487 | 36 | |
mCCI 3+ | 118 | 8.7 | 119 | 8.7 |
Older five-year survivors diagnosed 1990–1994 with early stage I and II breast cancer at age 65 or older followed for 10 years beginning five years after index date (date of breast cancer diagnosis).
Comparison cohort matched for health system and age, who were free of breast cancer at matched index date and followed for 10 years beginning five years after index date.
Women may be counted in multiple comorbidities.
Prevalent breast cancer at index date excluded.
Prevalent breast cancer at index date excluded from modified Charlson Comorbidity Index (mCCI), which is calculated from the sum of comorbidity weights listed in the table (Charlson et al 1987).